| Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript |
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Strategy Mike Exton - Chief Executive Officer and Director Scott Coiante - Senior Vice President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Roanna Ruiz - Leerink Partners Yasmeen Rahimi - Piper Sandler Yigal Nochomovitz - Citigroup Lander Gorrono - H.C. Wainwright Operator Welcome to the Lexicon Pharmaceuticals First Quarter 2025 Financial Results Conference Call. |
seekingalpha.com |
2025-05-14 01:47:21 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates |
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.20 per share a year ago. |
zacks.com |
2025-05-13 22:10:36 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates |
Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2025, and provided an update on key corporate milestones and accomplishments. “We began 2025 delivering on three of our goals for this year, including most recently an exclusive licensing agreement with Novo Nordisk for LX9851 in obesity and related disorders,” said Mike Exton, Ph.D. |
globenewswire.com |
2025-05-13 20:00:00 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference |
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET. |
globenewswire.com |
2025-05-06 20:30:00 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 |
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. |
globenewswire.com |
2025-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? |
The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk. |
zacks.com |
2025-04-02 15:20:34 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference |
THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, April 9, at 8:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/. |
globenewswire.com |
2025-04-02 12:00:00 |
Czytaj oryginał (ang.) |
| Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk |
Lexicon Pharmaceuticals Inc. LXRX stock is trading higher on Friday. |
benzinga.com |
2025-03-28 11:02:21 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 |
Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments |
globenewswire.com |
2025-03-28 09:30:00 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 |
THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 in Miami on Wednesday, March 12, at 10:00 a.m. ET. |
globenewswire.com |
2025-03-07 10:30:00 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call Transcript |
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q4 2024 Earnings Conference Call March 6, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Strategy Mike Exton - Chief Executive Officer and Director Scott Coiante - Senior Vice President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Joseph Stringer - Needham & Co. Joe Pantginis - H.C. Wainwright Andrew Tsai - Jefferies Operator Welcome to the Lexicon Pharmaceuticals Fourth Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2025-03-07 00:52:54 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates |
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.20 per share a year ago. |
zacks.com |
2025-03-06 20:11:06 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates |
Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development |
globenewswire.com |
2025-03-06 18:00:00 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 |
THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and full year 2024 financial results on Thursday, March 6, 2025 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. |
globenewswire.com |
2025-03-04 18:15:00 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain |
Pilavapadin achieved meaningful pain reduction versus placebo and was well-tolerated in the 10 mg dose, meeting the Company's objectives for the study Advancement of 10 mg dose into Phase 3 development in DPNP supported by both PROGRESS and RELIEF DPN-1 studies, which collectively enrolled approximately 600 pilavapadin-treated patients Conference call and webcast at 8:00 a.m. ET THE WOODLANDS, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced topline results from the PROGRESS Phase 2b study evaluating pilavapadin (LX9211), an oral, non-opioid investigational adaptor-associated kinase 1 (AAK1) inhibitor in adult patients with moderate to severe diabetic peripheral neuropathic pain (DPNP). |
globenewswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain |
THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will hold a conference call and webcast on Monday, March 3, 2025 at 8:00 a.m. ET to share topline results from the Phase 2b PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension in PatientS with Diabetic Peripheral Neuropathic Pain) study evaluating pilavapadin (LX9211), an oral, non-opioid investigational adaptor-associated kinase 1 (AAK1) inhibitor in adult patients with moderate to severe diabetic peripheral neuropathic pain (DPNP). |
globenewswire.com |
2025-03-02 18:13:00 |
Czytaj oryginał (ang.) |
| Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) |
Data reinforce unique clinical advantages of sotagliflozin Published study is aligned with research presented in December 2024 at the American Society of Hematology showing clinical benefits of sotagliflozin compared to empagliflozin THE WOODLANDS, Texas, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to reduce the risks of life-threatening cardiovascular outcomes. The findings from the study, “Reduction in Major Adverse Cardiovascular Events with Sotagliflozin: A Prespecified Analysis of the SCORED Randomized Trial,” concluded that the ischemic benefit of sotagliflozin on both heart attack (myocardial infarction, or MI), and stroke reduction has not been shown by other SGLT inhibitors. |
globenewswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain |
Event will feature insights on LX9211, Lexicon's novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP Event will feature insights on LX9211, Lexicon's novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP |
globenewswire.com |
2025-01-21 10:00:00 |
Czytaj oryginał (ang.) |
| Lexicon Appoints Scott Coiante as Chief Financial Officer |
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. |
globenewswire.com |
2025-01-02 10:00:00 |
Czytaj oryginał (ang.) |
| US FDA declines to approve Lexicon Pharma's add-on diabetes drug |
The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday. |
reuters.com |
2024-12-20 18:46:38 |
Czytaj oryginał (ang.) |
| Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) |
THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Zynquista™ (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). This expected communication from the FDA aligns with the company's previously disclosed strategic decision to discontinue launch preparations for Zynquista and focus solely on its clinical development pipeline. |
globenewswire.com |
2024-12-20 18:30:00 |
Czytaj oryginał (ang.) |
| Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) |
Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule |
globenewswire.com |
2024-11-26 10:00:00 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals to Participate in December Investor Conferences |
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon's chief executive officer and director, will present at two upcoming investor conferences in December. |
globenewswire.com |
2024-11-25 18:15:00 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development |
Lexicon Pharmaceuticals said on Friday it would reduce its workforce by about 60%, effective Dec. 31, to eliminate commercial activities and focus on drug development. |
reuters.com |
2024-11-22 09:47:04 |
Czytaj oryginał (ang.) |
| Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA |
Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions |
globenewswire.com |
2024-11-22 09:32:00 |
Czytaj oryginał (ang.) |
| Lexicon Appoints Ivan H. Cheung to Board of Directors |
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. |
globenewswire.com |
2024-11-20 18:05:00 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript |
Start Time: 17:00 January 1, 0000 5:55 PM ET Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q3 2024 Earnings Call November 12, 2024, 17:00 PM ET Company Participants Mike Exton - CEO and Director Tom Garner - SVP and Chief Commercial Officer Craig Granowitz - SVP and Chief Medical Officer Alan Main - EVP, Innovation and Chemical Sciences Lisa DeFrancesco - Head, IR and Corporate Strategy Conference Call Participants Andrew Tsai - Jeffries Joseph Stringer - Needham and Company Joe Pantginis - H.C. Wainwright Yigal Nochomovitz - Citigroup Roanna Ruiz - Leerink Partners Operator Good day, and welcome to the Lexicon Pharmaceuticals Third Quarter 2024 Results Conference Call. |
seekingalpha.com |
2024-11-12 22:39:05 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates |
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. |
zacks.com |
2024-11-12 20:26:07 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update |
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe |
globenewswire.com |
2024-11-12 18:05:00 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference |
THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference. Lexicon management including Mike Exton, Lexicon's chief executive officer and director will participate in a moderated discussion on Wednesday, November 20, 2024, at 9:00 am GT. |
globenewswire.com |
2024-11-06 10:00:00 |
Czytaj oryginał (ang.) |
| Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease |
People with T1D and CKD treated with sotagliflozin and insulin had similar lowering effects on glycated hemoglobin (HbA1c), the primary endpoint, as people with T1D who do not have CKD |
globenewswire.com |
2024-11-05 18:05:00 |
Czytaj oryginał (ang.) |
| Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease |
THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin), an oral SGLT1/SGLT2 inhibitor, as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). The Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, as defined in the voting question as having estimated glomerular filtration rate (eGFR) > 45 to 60 mL/min/1.73 m2 and urine albumin-to-creatinine ratio (uACR) > 30mg/g. |
globenewswire.com |
2024-10-31 20:54:00 |
Czytaj oryginał (ang.) |
| FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes |
Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease. |
reuters.com |
2024-10-31 18:54:06 |
Czytaj oryginał (ang.) |
| Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe |
-Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments |
globenewswire.com |
2024-10-16 20:35:00 |
Czytaj oryginał (ang.) |
| Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe |
Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH , Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets outside of the United States and Europe. Sotagliflozin was approved by the U.S. Food and Drug Administration in May 2023 to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. |
prnewswire.com |
2024-10-16 20:34:00 |
Czytaj oryginał (ang.) |
| Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress |
Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon's novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population |
globenewswire.com |
2024-09-27 12:00:00 |
Czytaj oryginał (ang.) |
| Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer |
THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024. A search for a new chief financial officer is ongoing. |
globenewswire.com |
2024-09-16 12:00:00 |
Czytaj oryginał (ang.) |
| New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes |
Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin |
globenewswire.com |
2024-09-10 12:00:00 |
Czytaj oryginał (ang.) |